VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2016

Jan 29, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2016-01-27

Reporting Person: BOGER JOSHUA S (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-01-27	Common Stock	M	11200	$35.64	Acquired	276484	Direct
2016-01-27	Common Stock	S	700	$90.70	Disposed	275784	Direct
2016-01-27	Common Stock	S	3300	$92.04	Disposed	272484	Direct
2016-01-27	Common Stock	S	2400	$93.00	Disposed	270084	Direct
2016-01-27	Common Stock	S	2600	$94.10	Disposed	267484	Direct
2016-01-27	Common Stock	S	2100	$94.94	Disposed	265384	Direct
2016-01-27	Common Stock	S	100	$95.71	Disposed	265284	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-01-27	Stock Option (Right to Buy)	$35.64	M	11200	Disposed	2016-02-01	Common Stock (11200)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	13286	Indirect
Common Stock	122700	Indirect

Footnotes

F1: Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $90.70 (range $90.57 to $91.23).

F3: Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4: Open market sales reported on this line occurred at a weighted average price of $92.04 (range $91.61 to $92.60).

F5: Open market sales reported on this line occurred at a weighted average price of $93.00 (range $92.61 to $93.51).

F6: Open market sales reported on this line occurred at a weighted average price of $94.10 (range $93.63 to $94.53).

F7: Open market sales reported on this line occurred at a weighted average price of $94.94 (range $94.65 to $95.31).

F8: Fully vested.